CFM
CRL icon

Catalyst Funds Management’s Charles River Laboratories CRL Stock Holding History

Catalyst Funds Management’s Portfolio CRL Stock Details CRL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$215K Buy
+950
New +$169K 0.01% 577
2025
Q2 		– Sell
-10,800
Closed -$1.63M – 497
2025
Q1 		$1.63M Buy
+10,800
New +$1.81M 0.43% 68

Other funds holding CRL

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
Harris Associates
Harris Associates Chicago, Illinois $75.4B AUM 14.46% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Allspring Global Investments
Allspring Global Investments Charlotte, North Carolina $65.2B AUM 39.42% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
AI
Ariel Investments Chicago, Illinois $10B AUM 42.59% 1-Year Est. Return

Catalyst Funds Management's CRL Position: Q2 2026 in Review

Catalyst Funds Management opened a new position in Charles River Laboratories (CRL) in Q2 2026: 950 shares worth $215K. The stake represents 0.01% of the portfolio and ranks #577 among its holdings. This is a return to the name: Catalyst Funds Management previously reported a position in CRL as recently as Q1 2025.

Catalyst Funds Management first reported a position in CRL in Q1 2025 and has held it in 2 quarters since. The position peaked at $1.63M in Q1 2025. 570 funds tracked by Wall St. Rank hold CRL as of Q2 2026.

  • Catalyst Funds Management held 950 shares of Charles River Laboratories worth $215K as of Q2 2026.
  • Charles River Laboratories was a new Catalyst Funds Management position in Q2 2026.
  • Charles River Laboratories made up 0.01% of Catalyst Funds Management's portfolio in Q2 2026, its #577 holding.
  • Catalyst Funds Management first reported a position in Charles River Laboratories in Q1 2025 and has held it in 2 quarters since.
  • Catalyst Funds Management's Charles River Laboratories position peaked at $1.63M in Q1 2025.
  • 570 funds tracked by Wall St. Rank held Charles River Laboratories as of Q2 2026.

Based on Catalyst Funds Management's 13F filing for Q2 2026, filed 10 Aug 2026.